Propecia Generic For Male Pattern Baldness

The drug propecia generic was originally intended for treating prostate enlargement or benign prostatic hyperplasia. When its branded name Proscar was released in the market, it was noticed that men who were suffering from androgenic alopecia were also being treated by the drug.  It was then that the manufacturer took notice and created some clinical studies and found out that Proscar, which came at 5mg, which at lowered dosage, particularly 1mg, could help fight androgenic alopecia.  Several years later, the brand Propecia, an offshoot of the drug Proscar was approved by the Food and Drug Administration as a treatment for androgenic alopecia.

Who is propecia generic intended for?

Propecia generic is meant for men suffering from male pattern baldness and want to stop the progression of their hair loss.  Signs of male pattern baldness would be the thinning of hair on the front, the receding of hairline on the temples, and the formation of a bald spot on the crown.  In due time, this type of baldness will let you end up bald from top to front with a rim of hair at the sides and back.  propecia generic is effective against this type of hair loss because it is able to treat it at the root of the cause – the formation of the hormone dihydrotestosterone (DHT).  Basically, this hair loss treatment prevents your hair loss from getting any worse.  If your hair loss is due to androgenic alopecia, then this is the medication for you.  Consult your doctor to know what type of hair loss you are having. Read more…

Relistor may weaken the GI wall

When to beware

As all meds do, mythylnaltrexone bromide (Relistor) has its share of possible side effects, the most common being dizziness, flatulence, mild diarrhea, nausea, stomach pain, vomiting, and hyperhidrosis. Severe reactions include a serious case of any already mentioned, or allergic reactions.

Today, Health Canada and Wyeth Canada added a new possible adverse reaction to the list: a heightened risk of gastrointestinal perforation, especially in those with GI cancers and other conditions that could weaken the gastrointestinal wall.

When Relistor came onto the scene – it was approved by Health Canada on March 28, 2008 – it relieved opioid-induced constipation in palliative-care patients with incurable cancers, end-stage COPD from emphysema, heart failure, Alzheimer’s disease, and so on, when other laxative therapies could not – in under 30 minutes. Administered by subcutaneous injection, it blocks opioids from entering cells, allowing bowels to revert to normal function, while not interfering with the opioid’s ability to relieve pain.

The current warning advises discontinuing Relistor and seeking professional help if severe, persistent symptoms like abdominal pain intensified by movement, nausea and vomiting -- possibly accompanied by fever and chills – worsen, as these can be signs of GI perforation.

It makes one wonder, though, if the original studies on this drug should have lasted a wee bit longer than four months.
Milena Katz